Radiation and immunotherapy: Renewed allies in the war on cancer

Anticancer immunotherapy holds great promises, as long-term responses to interleukin-2 have been observed in metastatic melanoma and renal cell carcinoma patients. However, improving the relative low rates of such responses has constituted a great challenge. In our experience, high-dose radiation co...

Descripción completa

Detalles Bibliográficos
Autores principales: Seung, Steven K., Curti, Brendan, Crittenden, Marka, Urba, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525632/
https://www.ncbi.nlm.nih.gov/pubmed/23264923
http://dx.doi.org/10.4161/onci.21746
_version_ 1782253452108234752
author Seung, Steven K.
Curti, Brendan
Crittenden, Marka
Urba, Walter
author_facet Seung, Steven K.
Curti, Brendan
Crittenden, Marka
Urba, Walter
author_sort Seung, Steven K.
collection PubMed
description Anticancer immunotherapy holds great promises, as long-term responses to interleukin-2 have been observed in metastatic melanoma and renal cell carcinoma patients. However, improving the relative low rates of such responses has constituted a great challenge. In our experience, high-dose radiation combined with interleukin-2 provided encouraging results that are worth exploring further.
format Online
Article
Text
id pubmed-3525632
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35256322012-12-21 Radiation and immunotherapy: Renewed allies in the war on cancer Seung, Steven K. Curti, Brendan Crittenden, Marka Urba, Walter Oncoimmunology Author's View Anticancer immunotherapy holds great promises, as long-term responses to interleukin-2 have been observed in metastatic melanoma and renal cell carcinoma patients. However, improving the relative low rates of such responses has constituted a great challenge. In our experience, high-dose radiation combined with interleukin-2 provided encouraging results that are worth exploring further. Landes Bioscience 2012-12-01 /pmc/articles/PMC3525632/ /pubmed/23264923 http://dx.doi.org/10.4161/onci.21746 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Seung, Steven K.
Curti, Brendan
Crittenden, Marka
Urba, Walter
Radiation and immunotherapy: Renewed allies in the war on cancer
title Radiation and immunotherapy: Renewed allies in the war on cancer
title_full Radiation and immunotherapy: Renewed allies in the war on cancer
title_fullStr Radiation and immunotherapy: Renewed allies in the war on cancer
title_full_unstemmed Radiation and immunotherapy: Renewed allies in the war on cancer
title_short Radiation and immunotherapy: Renewed allies in the war on cancer
title_sort radiation and immunotherapy: renewed allies in the war on cancer
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525632/
https://www.ncbi.nlm.nih.gov/pubmed/23264923
http://dx.doi.org/10.4161/onci.21746
work_keys_str_mv AT seungstevenk radiationandimmunotherapyrenewedalliesinthewaroncancer
AT curtibrendan radiationandimmunotherapyrenewedalliesinthewaroncancer
AT crittendenmarka radiationandimmunotherapyrenewedalliesinthewaroncancer
AT urbawalter radiationandimmunotherapyrenewedalliesinthewaroncancer

Ejemplares similares